The estimated Net Worth of Melissa A. Starovasnik is at least $549 Tysiąc dollars as of 9 February 2023. Melissa Starovasnik owns over 1,732 units of Twist Bioscience Corp stock worth over $503,042 and over the last 3 years Melissa sold TWST stock worth over $45,829.
Melissa has made over 1 trades of the Twist Bioscience Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently Melissa sold 1,732 units of TWST stock worth $45,829 on 9 February 2023.
The largest trade Melissa's ever made was selling 1,732 units of Twist Bioscience Corp stock on 9 February 2023 worth over $45,829. On average, Melissa trades about 346 units every 0 days since 2021. As of 9 February 2023 Melissa still owns at least 11,340 units of Twist Bioscience Corp stock.
You can see the complete history of Melissa Starovasnik stock trades at the bottom of the page.
Melissa's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell oraz Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
Twist Bioscience Corp executives and other stock owners filed with the SEC include: